MedTrace Logo

SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)

NCT03842917 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2022-11-08

No results posted yet for this study

Summary

Bevacizumab is an anti-angiogenic treatment used to treat various solid cancers. Previous studies have shown that this treatment may have adverse effects like hypertension and proteinuria.

This is an exploratory study aiming to better understand the relationship between various biomarkers and blood pressure changes and proteinuria measured for 4 to 6 weeks after the first infusion of anti-VEGF therapy with bevacizumab.

Conditions

  • Patient Starting Bevacizumab
  • Cancer

Interventions

OTHER

Biological samples

Urine and blood samples

OTHER

Blood pressure measurement

Home blood pressure self-measurement and hospital blood pressure measurement

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Theodora BEJAN-ANGOULVANT, MD-PhD · University Hospital, Tours

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-26
Primary Completion
2022-04-27
Completion
2022-06-15

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03842917 on ClinicalTrials.gov